Press Releases


MOLOGEN, a biotechnology company, presented promising data on overall survival of patient subgroups from the IMPACT study with MGN1703. The findings are based on the analysis performed in 2013 and were shown for the...


MOLOGEN, a biotechnology company, announced today that data on long-term treated metastatic colorectal cancer patients from the IMPACT study will be presented at the ESMO Symposium on Immuno-Oncology 2014. The Symposium will take place on November...


  • Start of patient enrolment for IMPALA (phase III) colorectal cancer study
  • New generation of immunomodulators introduced for the first time
  • Financial situation remains stable
The biotechnology company MOLOGEN AG...


The LEISHDNAVAX consortium, with the biotechnology company MOLOGEN AG as a key partner, presented preclinical data of the leishmaniasis vaccine (MGN1331) in a poster at the International Meeting on Emerging Diseases and Surveillance (IMED) in...


MOLOGEN AG, a biotechnology company focused on cancer immunotherapy, has organized the first set of investigator meetings for the phase III IMPALA study. Study teams from all eight countries where the trial will be conducted attended the seminars in...


  • New generation of linear TLR-9 agonists
  • EnanDIM induces broad immune activation
  • Potential application in the fields of cancer and anti-infective therapies
  • Preclinical data presented for the first time on conference...


Two posters on clinical trials with the cancer immune therapy MGN1703 and one with the therapeutic cancer vaccine MGN1601 of the biotechnology company MOLOGEN AG have been accepted at the ESMO Congress in Madrid (September 26 – 30, 2014). Updated...


Displaying results 1 bis 7 von 24

Page 1

Page 2

Page 3

Page 4



Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

Distribution list

If you would like to receive our press releases, please click here.